The U.S. Food and Drug Administration today granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria. For patients who are suffering...
SAN FRANCISCO, Oct. 7, 2019 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and one in patients with...
YTX-7739 represents a novel, first-in-class, potentially disease-modifying therapy Data from Phase 1 study expected in the first quarter of 2020 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Yumanity Therapeutics, a company focused on protecting the vitality of the...
NEW YORK, Oct. 8, 2019 /PRNewswire/ — Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and...
Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. Cancer blocks the immune system preventing it...
CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque psoriasis. The company also announced...
Email
Text